@jgwonkim, this is a crucial post for anyone following the Korean pharmaceutical industry! Breaking down the legal definitions and requirements for "Innovative Pharmaceutical Companies" as defined by the Special Act on Fostering and Supporting the Pharmaceutical Industry is incredibly valuable.

The level of detail you've provided, citing specific articles and clauses, makes this an excellent resource for researchers, investors, and anyone interested in the regulatory landscape. It highlights the government's focus on R&D investment, ethical practices, and global competitiveness.

I'm particularly interested in the criteria around social responsibility and ethical conduct. How do you see these factors influencing the future of pharmaceutical innovation in Korea? Thanks for sharing this insightful legal overview!